Drugs / mRNA-1273 Variant-containing Formulation
mRNA-1273 Variant-containing Formulation
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06585241 | Sep 2024 → Dec 2026 expected | COVID-19 | ModernaTX, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mRNA-1273 Variant-containing Formulation | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06585241 ↗ |
| Modality | Messenger RNA (mRNA) | “mRNA-1273 COVID-19 vaccine” NCT06585241 ↗ |